Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 6,923 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Muscle Protein Synthetic Response to Protein, Muscle Protein Synthesis, Muscle Health, Protein Metabolism, Recreational Activities, Isotope Labeling
Interventions: Resistance Exercise, Potato and Beef, Bread and Beef, Beef; Behavioral · Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 19 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Cranial Neurosurgery
Interventions: Medtronic LINQII; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Infertility, Breast Cancer
Interventions: RPFNA; Procedure
Lead sponsor: University of Kansas; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Post-Traumatic Headache, Transcranial Magnetic Stimulation, Brain Injuries, Traumatic, Quality of Life
Interventions: Theta Burst Stimulation; Device
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Surgery
Interventions: BlockSynop surface electromyography device, Peripheral nerve block; Device · Procedure
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 0 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Migraine
Interventions: Cadwell Cascade 32 PRO; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Treatment Resistant Depression
Interventions: Active TBS-DLPFC, TBS-DMPFC; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Interventions: Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 17
States / cities: Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more

Conditions: Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions: PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: Cala Device; Device
Lead sponsor: Cala Health, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Burlingame, California

Conditions: Posttraumatic Stress Disorder, PTSD, Anxiety, Depression
Interventions: Transcranial Direct Current Stimulation (tDCS), Prolonged Exposure Therapy; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Sarcoma
Interventions: filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 60
States / cities: Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 47 more

Conditions: Smoking Cessation, HIV, Craving
Interventions: iTBS, TMS; Device
Lead sponsor: Gopalkumar Rakesh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Osteo Arthritis Knee
Interventions: Cranial Electrical Stimulation (CES), Sham-CES; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Rate Variability
Interventions: Heart Rate Variability - Biofeedback (HRV-BF), Health Promotion (HP); Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Los Angeles, California

Conditions: Anorexia Nervosa, Bulimia Nervosa
Interventions: Transcranial magnetic stimulation, Transcranial direct current stimulation; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID-19
Interventions: Auricular percutaneous neurostimulation; Device
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
Interventions: GM-CSF, Rituximab, NK Cell Infusion; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Subjective Cognitive Decline
Interventions: Internet-based Mindfulness-Based Stress Reduction (iMBSR), Internet-based Lifestyle Education (iLifeEd); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pediatric Cancer
Interventions: Weighted Blanket; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 4 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Sunitinib, GM-CSF, Cyclophosphamide, IMA901; Drug · Biological
Lead sponsor: Immatics Biotechnologies GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Pharmacological Study; Drug · Biological · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Female Sexual Dysfunction, Female Sexual Dysfunction Due to Physical Condition
Interventions: Transcutaneous electrical nerve stimulation - Tibial Nerve, Transcutaneous electrical nerve stimulation - Genital Nerve, Neutral and Erotic Film Clip Alternation; Device · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Diet Synergy in Muscle Protein Synthesis

A Study Of Subscalp Placement Of The LINQII Device

Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin

Theta Burst Stimulation for Headaches After Traumatic Brain Injury

Peripheral Regional Blockade and EMG

Stimulation of External Carotid Artery Circulation

Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor

TDCS-Augmented Prolonged Exposure Therapy

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

TMS for Smoking Cessation in PLWHA Cessation in People Living With HIV/AIDS (PLWHA)

Self Cranial Electrical Stimulation (CES) for Pain in Older Adults With Knee Osteoarthritis (Self CES for Knee Pain)

Impact of Community-Based Biofeedback Program on Drug Use and Mental Health Among People Experiencing Homelessness

Transcranial Treatments in Eating Disorders

Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Internet-based Mind-Body Training for Brain Health

Effect of Weighted Blankets on Anxiety for Pediatric Oncology Patients

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2